 Paul Maroni
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 39 | 2024 | 1034 | 3.880 |
Why?
| | Prostatectomy | 8 | 2019 | 104 | 1.530 |
Why?
| | Testicular Neoplasms | 7 | 2023 | 110 | 1.130 |
Why?
| | Urology | 3 | 2020 | 63 | 0.860 |
Why?
| | Embolism | 1 | 2021 | 41 | 0.710 |
Why?
| | Urethra | 1 | 2021 | 55 | 0.700 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 77 | 0.700 |
Why?
| | Androgen Antagonists | 4 | 2024 | 82 | 0.690 |
Why?
| | Laser Therapy | 1 | 2021 | 130 | 0.630 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1044 | 0.470 |
Why?
| | Kidney Medulla | 2 | 2005 | 35 | 0.470 |
Why?
| | Early Detection of Cancer | 5 | 2023 | 417 | 0.430 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 403 | 0.380 |
Why?
| | Urination Disorders | 1 | 2011 | 13 | 0.370 |
Why?
| | Prostate-Specific Antigen | 8 | 2020 | 161 | 0.370 |
Why?
| | Male | 56 | 2024 | 67309 | 0.360 |
Why?
| | Prostate | 7 | 2023 | 175 | 0.330 |
Why?
| | Oxalates | 2 | 2008 | 10 | 0.310 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2014 | 1462 | 0.290 |
Why?
| | Neoplasm Grading | 5 | 2021 | 305 | 0.290 |
Why?
| | Adenocarcinoma | 3 | 2022 | 938 | 0.270 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 219 | 0.270 |
Why?
| | Humans | 59 | 2024 | 136764 | 0.260 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1371 | 0.250 |
Why?
| | Kidney Tubules, Collecting | 1 | 2005 | 31 | 0.240 |
Why?
| | Oxalic Acid | 1 | 2004 | 4 | 0.230 |
Why?
| | Brachytherapy | 2 | 2016 | 121 | 0.230 |
Why?
| | Clinical Competence | 1 | 2012 | 1094 | 0.230 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 251 | 0.210 |
Why?
| | Androgens | 4 | 2024 | 187 | 0.200 |
Why?
| | Paraganglioma | 1 | 2022 | 52 | 0.180 |
Why?
| | Cell Hypoxia | 2 | 2015 | 226 | 0.180 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2022 | 89 | 0.180 |
Why?
| | Prolactin | 3 | 1997 | 96 | 0.170 |
Why?
| | Surveys and Questionnaires | 3 | 2017 | 5742 | 0.170 |
Why?
| | Adaptor Proteins, Vesicular Transport | 2 | 1997 | 45 | 0.170 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 134 | 0.170 |
Why?
| | Aged | 21 | 2021 | 23794 | 0.170 |
Why?
| | Orchiectomy | 3 | 2016 | 71 | 0.170 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2020 | 24 | 0.170 |
Why?
| | Middle Aged | 20 | 2021 | 33228 | 0.170 |
Why?
| | Risk Assessment | 4 | 2020 | 3432 | 0.160 |
Why?
| | Salvage Therapy | 2 | 2018 | 142 | 0.160 |
Why?
| | Biflavonoids | 1 | 2019 | 9 | 0.150 |
Why?
| | Stromal Cells | 1 | 2019 | 112 | 0.150 |
Why?
| | Proanthocyanidins | 1 | 2019 | 10 | 0.150 |
Why?
| | Catechin | 1 | 2019 | 24 | 0.150 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.150 |
Why?
| | Anthocyanins | 1 | 2019 | 33 | 0.150 |
Why?
| | Hospitals | 2 | 2023 | 685 | 0.150 |
Why?
| | Grape Seed Extract | 1 | 2019 | 44 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 54 | 0.150 |
Why?
| | Digital Rectal Examination | 1 | 2018 | 10 | 0.140 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2018 | 42 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1058 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 1997 | 428 | 0.140 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 190 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1997 | 134 | 0.140 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 188 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 13 | 0.130 |
Why?
| | Biopsy, Needle | 2 | 2016 | 189 | 0.130 |
Why?
| | Surgical Wound Infection | 2 | 2019 | 305 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.130 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.130 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 657 | 0.130 |
Why?
| | Plant Extracts | 1 | 2018 | 202 | 0.130 |
Why?
| | Medical Oncology | 1 | 2019 | 289 | 0.130 |
Why?
| | Radiology | 1 | 2019 | 180 | 0.120 |
Why?
| | Spectrum Analysis | 1 | 2016 | 91 | 0.120 |
Why?
| | Liver | 4 | 1997 | 1940 | 0.120 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.120 |
Why?
| | Prognosis | 7 | 2019 | 4013 | 0.120 |
Why?
| | Radiotherapy, Conformal | 1 | 2015 | 70 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 2 | 1997 | 647 | 0.120 |
Why?
| | Risk | 2 | 2015 | 908 | 0.110 |
Why?
| | Lymphatic Metastasis | 3 | 2014 | 351 | 0.110 |
Why?
| | HSP70 Heat-Shock Proteins | 2 | 2008 | 73 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 399 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 134 | 0.110 |
Why?
| | Biopsy | 4 | 2023 | 1124 | 0.110 |
Why?
| | Genomics | 1 | 2019 | 790 | 0.110 |
Why?
| | Leydig Cell Tumor | 1 | 2014 | 8 | 0.110 |
Why?
| | Cause of Death | 1 | 2016 | 430 | 0.110 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 26 | 0.110 |
Why?
| | Priapism | 1 | 2013 | 11 | 0.110 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 34 | 0.110 |
Why?
| | Optics and Photonics | 1 | 2014 | 42 | 0.110 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.100 |
Why?
| | Hypertension | 1 | 2022 | 1284 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 168 | 0.100 |
Why?
| | Extracellular Vesicles | 1 | 2015 | 145 | 0.100 |
Why?
| | Proline | 1 | 2013 | 79 | 0.100 |
Why?
| | Triglycerides | 1 | 2015 | 524 | 0.100 |
Why?
| | Treatment Outcome | 7 | 2018 | 10744 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2010 | 132 | 0.100 |
Why?
| | Telephone | 1 | 2013 | 170 | 0.100 |
Why?
| | Neoplasm Invasiveness | 4 | 2016 | 507 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 407 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2104 | 0.090 |
Why?
| | Signal Transduction | 4 | 2004 | 5075 | 0.090 |
Why?
| | Survival Rate | 4 | 2017 | 1962 | 0.090 |
Why?
| | Urothelium | 1 | 2011 | 37 | 0.090 |
Why?
| | Cell Line | 3 | 2008 | 2837 | 0.090 |
Why?
| | Lymph Nodes | 1 | 2014 | 489 | 0.090 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 42 | 0.090 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 80 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1163 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2008 | 185 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2011 | 73 | 0.090 |
Why?
| | Oxygen | 1 | 2015 | 930 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2020 | 7585 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2008 | 1094 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2022 | 217 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2010 | 56 | 0.080 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1231 | 0.080 |
Why?
| | Survival Analysis | 2 | 2016 | 1321 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1019 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2019 | 2639 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2009 | 283 | 0.080 |
Why?
| | Counseling | 1 | 2013 | 388 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 898 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 152 | 0.080 |
Why?
| | Survivors | 1 | 2013 | 487 | 0.080 |
Why?
| | Lymph Node Excision | 2 | 2014 | 170 | 0.080 |
Why?
| | Carcinoma | 1 | 2011 | 238 | 0.080 |
Why?
| | Lymphatic Diseases | 1 | 2009 | 22 | 0.080 |
Why?
| | Cystitis | 1 | 2009 | 22 | 0.080 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 34 | 0.070 |
Why?
| | Age Factors | 4 | 2017 | 3284 | 0.070 |
Why?
| | Logistic Models | 3 | 2019 | 2067 | 0.070 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 38 | 0.070 |
Why?
| | Patient Selection | 2 | 2018 | 690 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2013 | 761 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 1261 | 0.070 |
Why?
| | Databases, Factual | 3 | 2019 | 1351 | 0.070 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 3405 | 0.070 |
Why?
| | Image-Guided Biopsy | 2 | 2020 | 39 | 0.070 |
Why?
| | Adult | 12 | 2020 | 37630 | 0.070 |
Why?
| | Societies, Medical | 1 | 2011 | 816 | 0.070 |
Why?
| | Kidney Tubules, Proximal | 1 | 2008 | 127 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 278 | 0.070 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 161 | 0.070 |
Why?
| | Time Factors | 4 | 2014 | 6806 | 0.070 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2008 | 387 | 0.070 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 328 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 182 | 0.070 |
Why?
| | Radiotherapy Dosage | 2 | 2018 | 268 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2009 | 621 | 0.060 |
Why?
| | Animals | 11 | 2022 | 36823 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2016 | 5106 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2010 | 1314 | 0.060 |
Why?
| | Young Adult | 6 | 2020 | 13129 | 0.060 |
Why?
| | Isoflavones | 1 | 2005 | 26 | 0.060 |
Why?
| | Ear, Inner | 1 | 2005 | 48 | 0.060 |
Why?
| | Support Vector Machine | 2 | 2016 | 38 | 0.060 |
Why?
| | Mitotic Index | 2 | 2015 | 25 | 0.060 |
Why?
| | Body Fluids | 1 | 2005 | 66 | 0.060 |
Why?
| | History, 21st Century | 1 | 2006 | 212 | 0.060 |
Why?
| | Mice | 4 | 2022 | 17733 | 0.060 |
Why?
| | Informed Consent | 1 | 2006 | 172 | 0.060 |
Why?
| | Cell Count | 1 | 2005 | 323 | 0.060 |
Why?
| | Urinary Incontinence | 1 | 2005 | 66 | 0.060 |
Why?
| | Growth | 1 | 2004 | 60 | 0.060 |
Why?
| | Disease Progression | 2 | 2018 | 2750 | 0.060 |
Why?
| | MAP Kinase Signaling System | 2 | 2008 | 320 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 401 | 0.050 |
Why?
| | Propensity Score | 2 | 2016 | 289 | 0.050 |
Why?
| | United States | 5 | 2019 | 14691 | 0.050 |
Why?
| | Mass Screening | 2 | 2015 | 1267 | 0.050 |
Why?
| | Receptors, Nicotinic | 1 | 2005 | 334 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2019 | 2472 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1507 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 888 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 1997 | 434 | 0.050 |
Why?
| | Transcriptional Regulator ERG | 1 | 2022 | 18 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2004 | 183 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2122 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1935 | 0.050 |
Why?
| | Rats, Wistar | 3 | 1997 | 455 | 0.050 |
Why?
| | Rats | 6 | 2005 | 5639 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 2022 | 123 | 0.050 |
Why?
| | Cell Survival | 2 | 2019 | 1114 | 0.040 |
Why?
| | Intestines | 1 | 2004 | 357 | 0.040 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1997 | 12 | 0.040 |
Why?
| | Shc Signaling Adaptor Proteins | 2 | 1997 | 12 | 0.040 |
Why?
| | Testosterone | 2 | 2015 | 401 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2001 | 116 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2001 | 283 | 0.040 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1272 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2022 | 214 | 0.040 |
Why?
| | Adolescent | 5 | 2022 | 21382 | 0.040 |
Why?
| | Fever | 1 | 2001 | 306 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 224 | 0.040 |
Why?
| | Reperfusion | 2 | 1996 | 40 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 327 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2001 | 313 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2834 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2005 | 648 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2023 | 15504 | 0.040 |
Why?
| | Jagged-1 Protein | 1 | 2019 | 23 | 0.040 |
Why?
| | Geography | 1 | 2019 | 198 | 0.040 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 15 | 0.040 |
Why?
| | Receptor, Notch1 | 1 | 2019 | 64 | 0.040 |
Why?
| | Zinc | 1 | 2022 | 297 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 98 | 0.040 |
Why?
| | Tissue Kallikreins | 1 | 2018 | 2 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 49 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 2019 | 76 | 0.040 |
Why?
| | Quality of Life | 2 | 2013 | 2878 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2001 | 441 | 0.040 |
Why?
| | Kallikreins | 1 | 2018 | 29 | 0.040 |
Why?
| | Enzyme Activation | 4 | 2008 | 810 | 0.040 |
Why?
| | Janus Kinase 2 | 1 | 1997 | 32 | 0.040 |
Why?
| | Enzyme Induction | 1 | 1997 | 90 | 0.040 |
Why?
| | MAP Kinase Kinase 1 | 1 | 1997 | 75 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2005 | 4190 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2022 | 769 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 142 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 953 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 47 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 562 | 0.030 |
Why?
| | Phosphorylation | 4 | 2008 | 1758 | 0.030 |
Why?
| | Phenotype | 3 | 2010 | 3188 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7572 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 752 | 0.030 |
Why?
| | Protein Kinase C | 2 | 1994 | 261 | 0.030 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 33 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 46 | 0.030 |
Why?
| | Altitude | 1 | 2019 | 485 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 138 | 0.030 |
Why?
| | Female | 7 | 2021 | 72787 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2019 | 572 | 0.030 |
Why?
| | Ischemia | 2 | 1996 | 407 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 685 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1995 | 137 | 0.030 |
Why?
| | Proteins | 2 | 1997 | 1008 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 965 | 0.030 |
Why?
| | Colorado | 2 | 2015 | 4518 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 293 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1733 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 696 | 0.030 |
Why?
| | Needles | 1 | 2014 | 59 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 10326 | 0.030 |
Why?
| | Radiotherapy | 1 | 2014 | 201 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 218 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 88 | 0.030 |
Why?
| | Aging | 3 | 2010 | 1861 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1995 | 417 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 367 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1995 | 385 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 521 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 512 | 0.020 |
Why?
| | Child | 3 | 2022 | 21822 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1059 | 0.020 |
Why?
| | Reoperation | 1 | 2014 | 573 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 474 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 487 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2011 | 317 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 317 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 184 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2551 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 396 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1031 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5701 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 514 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 11 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 951 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2001 | 162 | 0.020 |
Why?
| | Prostatitis | 1 | 2009 | 18 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 60 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 616 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 34 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2792 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 576 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2009 | 113 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1282 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 21 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 974 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3555 | 0.020 |
Why?
| | Immunoblotting | 2 | 2001 | 306 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2013 | 651 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1301 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 55 | 0.020 |
Why?
| | Tyrosine | 2 | 2001 | 222 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1692 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2009 | 150 | 0.020 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 140 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1225 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2009 | 200 | 0.020 |
Why?
| | Glutathione | 1 | 2009 | 356 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2008 | 2831 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 139 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2179 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1283 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 622 | 0.020 |
Why?
| | Models, Animal | 1 | 2008 | 384 | 0.020 |
Why?
| | Phosphotyrosine | 2 | 1996 | 39 | 0.020 |
Why?
| | Chinchilla | 1 | 2005 | 34 | 0.020 |
Why?
| | Equol | 1 | 2005 | 5 | 0.020 |
Why?
| | Guinea Pigs | 1 | 2005 | 158 | 0.020 |
Why?
| | Swine | 1 | 2008 | 773 | 0.010 |
Why?
| | Antioxidants | 1 | 2009 | 584 | 0.010 |
Why?
| | Bladder Exstrophy | 1 | 2004 | 17 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2013 | 1097 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 2004 | 28 | 0.010 |
Why?
| | Bicarbonates | 1 | 2004 | 44 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1481 | 0.010 |
Why?
| | Meat | 1 | 2005 | 94 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4143 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6033 | 0.010 |
Why?
| | Meningomyelocele | 1 | 2004 | 59 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2667 | 0.010 |
Why?
| | Body Height | 1 | 2004 | 199 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 1112 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 780 | 0.010 |
Why?
| | Receptor, IGF Type 1 | 1 | 2001 | 65 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9398 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11000 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 487 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2001 | 844 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2605 | 0.010 |
Why?
| | ErbB Receptors | 1 | 2001 | 613 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2644 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 3946 | 0.010 |
Why?
| | GRB2 Adaptor Protein | 1 | 1996 | 13 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1996 | 45 | 0.010 |
Why?
| | Neurons | 1 | 2005 | 1587 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 159 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2486 | 0.010 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 216 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 253 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1995 | 147 | 0.010 |
Why?
| | Densitometry | 1 | 1994 | 36 | 0.010 |
Why?
| | Phosphotransferases | 1 | 1994 | 24 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1994 | 100 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 269 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1994 | 114 | 0.010 |
Why?
| | Ornithine Decarboxylase | 1 | 1994 | 10 | 0.010 |
Why?
| | Genes, myc | 1 | 1994 | 48 | 0.010 |
Why?
| | Molecular Weight | 1 | 1994 | 335 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 345 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 226 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1994 | 371 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1663 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1996 | 964 | 0.010 |
Why?
| | Gene Expression | 1 | 1994 | 1500 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1994 | 1430 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1995 | 1990 | 0.000 |
Why?
|
|
Maroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|